CEL-SCI Corp Files 8-K: Reporting Other Events & Exhibits
Ticker: CVM · Form: 8-K · Filed: Jul 26, 2024 · CIK: 725363
Sentiment: neutral
Topics: 8-k, reporting, sec-filing
Related Tickers: SCI
TL;DR
CEL-SCI filed an 8-K, standard reporting stuff, no major news yet.
AI Summary
CEL-SCI Corporation filed an 8-K on July 26, 2024, reporting other events and financial statements/exhibits. The filing does not contain specific details on new events or financial figures within the provided text, but indicates a standard reporting update.
Why It Matters
This filing serves as a routine update for investors, indicating that CEL-SCI Corporation has submitted necessary documentation to the SEC regarding its operations and financial status.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report and does not disclose any new material events, risks, or financial changes.
Key Players & Entities
- CEL-SCI CORPORATION (company) — Registrant
- 0001654954-24-009490 (filing_id) — Accession Number
- July 26, 2024 (date) — Date of Report
- 8229 Boone Blvd. #802 Vienna, VA 22182 (address) — Principal executive offices
- 7035069460 (phone_number) — Business Phone
FAQ
What is the primary purpose of this 8-K filing for CEL-SCI Corporation?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of July 26, 2024.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported in this filing is July 26, 2024.
What is the principal executive office address for CEL-SCI Corporation?
The principal executive office address for CEL-SCI Corporation is 8229 Boone Blvd. #802 Vienna, VA 22182.
What is the telephone number for CEL-SCI Corporation's principal executive offices?
The telephone number for CEL-SCI Corporation's principal executive offices is (703) 506-9460.
What is the SIC code and industry classification for CEL-SCI Corporation?
CEL-SCI Corporation has a Standard Industrial Classification (SIC) code of [2836] for BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Stats: 460 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-07-26 17:27:40
Filing Documents
- cvm_8k.htm (8-K) — 22KB
- cvm_ex99.htm (EX-99) — 14KB
- cvm_ex99img2.jpg (GRAPHIC) — 62KB
- cvm_ex99img3.jpg (GRAPHIC) — 4KB
- 0001654954-24-009490.txt ( ) — 253KB
- cvm-20240726.xsd (EX-101.SCH) — 6KB
- cvm-20240726_lab.xml (EX-101.LAB) — 14KB
- cvm-20240726_cal.xml (EX-101.CAL) — 1KB
- cvm-20240726_pre.xml (EX-101.PRE) — 9KB
- cvm-20240726_def.xml (EX-101.DEF) — 2KB
- cvm_8k_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. On July 26, 2024, CEL-SCI Corporation (the "Company") issued a press release reporting positive results from a bias analysis conducted for its concluded Phase 3 study of Multikine (Leukocyte Interleukin, Injection)* in the treatment of head and neck cancer. Conducting a bias analysis is a standard process used to identify, assess, and address potential sources of bias that could influence the outcomes and interpretations of study results. The goal of a bias analysis is to ensure that the trial's findings are reliable, the conclusions are valid, and to minimize the risk that bias has distorted the results.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 99 Press Release re. Bias analysis results 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 26, 2024 CEL-SCI CORPORATION By: /s/ Patricia Prichep Patricia B. Prichep Senior Vice President of Operations 3